Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer-Reference-Cited by-同舟云学术

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Published:2018-10-12 Issue:1 Volume:25 Page:277-289
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Croessmann Sarah,Formisano Luigi,Kinch Lisa N.^ORCID,Gonzalez-Ericsson Paula I.^ORCID,Sudhan Dhivya R.,Nagy Rebecca J.,Mathew Aju,Bernicker Eric H.^ORCID,Cristofanilli Massimo,He Jie,Cutler Richard E.,Lalani Alshad S.,Miller Vincent A.,Lanman Richard B.^ORCID,Grishin Nick V.,Arteaga Carlos L.

Funder

HHS | NIH | National Cancer Institute (NCI)

Vanderbilt-Ingram Cancer Center (VICC)

Susan G. Komen for the Cure (Susan G. Komen)

Breast Cancer Research Foundation (BCRF)

HHS | National Institutes of Health (NIH)

Welch Foundation (Robert A. Welch Foundation)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis;Frontiers in Oncology;2024-08-29

2. ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity;Virchows Archiv;2024-08-28

3. Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2;2024-08-02

4. Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2;2024-08-02

5. O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer;Nature Communications;2024-07-03